Literature DB >> 25327287

Axl as a downstream effector of TGF-β1 via PI3K/Akt-PAK1 signaling pathway promotes tumor invasion and chemoresistance in breast carcinoma.

Yanyan Li1, Li Jia, Chen Liu, Yanxin Gong, Dongliang Ren, Ning Wang, Xu Zhang, Yongfu Zhao.   

Abstract

The invasion and chemoresistance are crucial causes of morbidity and death for cancer patients. Axl is closely associated with malignant phenotype of breast tumor cells, including invasiveness and metastasis. Both breast cancer cell line and tissue displayed increased expression of Axl, especially in highly metastatic breast cancer. On the contrary, experimental inhibition of Axl or transforming growth factor beta 1 (TGF-β1) by RNAi assay could suppress cell invasion ability and chemoresistance. Moreover, the up-regulation of Axl was induced by TGF-β1, further activated phosphatidylinositol 3-kinase (PI3K)/Akt and PAK1 translocation, and resulted in greater cell motility, invasion, and chemoresistance in vitro and in vivo. After the detection and statistics in human breast cancer specimens, we found that the Axl expression was closely correlated with TGF-β1 level, tumor differentiation, lymph node metastasis, and clinical stage (p < 0.01). Our findings support the possibility that Axl is a significant regulator of invasion and chemosensitivity, and it means by targeting Axl or its related signaling pathways, we can reduce the invasion and chemosensitivity of breast tumor.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25327287     DOI: 10.1007/s13277-014-2677-3

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  35 in total

1.  Structural basis for Gas6-Axl signalling.

Authors:  Takako Sasaki; Pjotr G Knyazev; Naomi J Clout; Yuri Cheburkin; Walter Göhring; Axel Ullrich; Rupert Timpl; Erhard Hohenester
Journal:  EMBO J       Date:  2005-12-15       Impact factor: 11.598

2.  The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma.

Authors:  Alvarez Hector; Elizabeth A Montgomery; Collins Karikari; Marcia Canto; Kerry B Dunbar; Jean S Wang; Georg Feldmann; Seung-Mo Hong; Michael C Haffner; Alan K Meeker; Sacha J Holland; Jiaxin Yu; Thilo J Heckrodt; Jing Zhang; Pingyu Ding; Dane Goff; Rajinder Singh; Juan Carlos Roa; Arivusudar Marimuthu; Gregory J Riggins; James R Eshleman; Barry D Nelkin; Akhilesh Pandey; Anirban Maitra
Journal:  Cancer Biol Ther       Date:  2010-11-15       Impact factor: 4.742

Review 3.  Axl-dependent signalling: a clinical update.

Authors:  Vyacheslav A Korshunov
Journal:  Clin Sci (Lond)       Date:  2012-04       Impact factor: 6.124

Review 4.  PI3K-Akt pathway: its functions and alterations in human cancer.

Authors:  M Osaki; M Oshimura; H Ito
Journal:  Apoptosis       Date:  2004-11       Impact factor: 4.677

5.  Differential expression of Axl and correlation with invasion and multidrug resistance in cancer cells.

Authors:  Yongfu Zhao; Xiance Sun; Lili Jiang; Fengjuan Yang; Zhaohai Zhang; Li Jia
Journal:  Cancer Invest       Date:  2012-04-10       Impact factor: 2.176

6.  Multiple roles for the receptor tyrosine kinase axl in tumor formation.

Authors:  Sacha J Holland; Mark J Powell; Christian Franci; Emily W Chan; Annabelle M Friera; Robert E Atchison; John McLaughlin; Susan E Swift; Erlina S Pali; George Yam; Stephen Wong; Joe Lasaga; Mary R Shen; Simon Yu; Weiduan Xu; Yasumichi Hitoshi; Jakob Bogenberger; Jacques E Nör; Donald G Payan; James B Lorens
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

Review 7.  TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer.

Authors:  Rachel M A Linger; Amy K Keating; H Shelton Earp; Douglas K Graham
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

Review 8.  [Gas-6 and protein S: vitamin K-dependent factors and ligands for the TAM tyrosine kinase receptors family].

Authors:  Omar Benzakour; Aurore Gely; Romain Lara; Valérie Coronas
Journal:  Med Sci (Paris)       Date:  2007-10       Impact factor: 0.818

9.  Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer.

Authors:  R M A Linger; R A Cohen; C T Cummings; S Sather; J Migdall-Wilson; D H G Middleton; X Lu; A E Barón; W A Franklin; D T Merrick; P Jedlicka; D DeRyckere; L E Heasley; D K Graham
Journal:  Oncogene       Date:  2012-08-13       Impact factor: 9.867

10.  The oncogenic TBX3 is a downstream target and mediator of the TGF-β1 signaling pathway.

Authors:  Jarod Li; Marc S Weinberg; Luiz Zerbini; Sharon Prince
Journal:  Mol Biol Cell       Date:  2013-09-11       Impact factor: 4.138

View more
  16 in total

1.  Peroxisome proliferator-activated receptor-γ agonist troglitazone suppresses transforming growth factor-β1 signalling through miR-92b upregulation-inhibited Axl expression in human keloid fibroblasts in vitro.

Authors:  Hua-Yu Zhu; Wen-Dong Bai; Jun Li; Ke Tao; Hong-Tao Wang; Xue-Kang Yang; Jia-Qi Liu; Yun-Chuan Wang; Ting He; Song-Tao Xie; Da-Hai Hu
Journal:  Am J Transl Res       Date:  2016-08-15       Impact factor: 4.060

2.  Demethylzeylasteral (T-96) inhibits triple-negative breast cancer invasion by blocking the canonical and non-canonical TGF-β signaling pathways.

Authors:  Liu Li; Yi Ji; Junting Fan; Furong Li; Yan Li; Mianhua Wu; Haibo Cheng; Changliang Xu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-02-06       Impact factor: 3.000

3.  miR-21 is involved in transforming growth factor β1-induced chemoresistance and invasion by targeting PTEN in breast cancer.

Authors:  Xiaomeng Dai; Mao Fang; Shuang Li; Yongrong Yan; Ying Zhong; Bin Du
Journal:  Oncol Lett       Date:  2017-09-20       Impact factor: 2.967

Review 4.  Does Axl have potential as a therapeutic target in pancreatic cancer?

Authors:  Wenting Du; Rolf A Brekken
Journal:  Expert Opin Ther Targets       Date:  2018-10-03       Impact factor: 6.902

5.  AXL Is a Key Factor for Cell Plasticity and Promotes Metastasis in Pancreatic Cancer.

Authors:  Wenting Du; Natalie Z Phinney; Huocong Huang; Zhaoning Wang; Jill Westcott; Jason E Toombs; Yuqing Zhang; Muhammad S Beg; Thomas M Wilkie; James B Lorens; Rolf A Brekken
Journal:  Mol Cancer Res       Date:  2021-04-02       Impact factor: 5.852

6.  Small molecule inhibition of Axl receptor tyrosine kinase potently suppresses multiple malignant properties of glioma cells.

Authors:  Mikaella Vouri; Qian An; Matthew Birt; Geoffrey J Pilkington; Sassan Hafizi
Journal:  Oncotarget       Date:  2015-06-30

7.  Characterization of site-specific glycosylation of secreted proteins associated with multi-drug resistance of gastric cancer.

Authors:  Jian Wu; Hongqiang Qin; Ting Li; Kai Cheng; Jiaqiang Dong; Miaomiao Tian; Na Chai; Hao Guo; Jinjing Li; Xin You; Mingming Dong; Mingliang Ye; Yongzhan Nie; Hanfa Zou; Daiming Fan
Journal:  Oncotarget       Date:  2016-05-03

Review 8.  Transforming growth factor β as regulator of cancer stemness and metastasis.

Authors:  Claudia Bellomo; Laia Caja; Aristidis Moustakas
Journal:  Br J Cancer       Date:  2016-08-18       Impact factor: 7.640

9.  Cyclooxygenase-2 in tumor-associated macrophages promotes metastatic potential of breast cancer cells through Akt pathway.

Authors:  Lu Gan; Zhu Qiu; Jing Huang; Yunhai Li; Hongyan Huang; Tingxiu Xiang; Jingyuan Wan; Tianli Hui; Yong Lin; Hongzhong Li; Guosheng Ren
Journal:  Int J Biol Sci       Date:  2016-11-26       Impact factor: 6.580

10.  AXL Is a Potential Target for the Treatment of Intestinal Fibrosis.

Authors:  Calen A Steiner; Eva S Rodansky; Laura A Johnson; Jeffrey A Berinstein; Kelly C Cushing; Sha Huang; Jason R Spence; Peter D R Higgins
Journal:  Inflamm Bowel Dis       Date:  2021-02-16       Impact factor: 7.290

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.